AUTHOR=Liu Chaoyuan , Lu Min , Yang Yang , Wang Xiang , Ma Fang , Liu Xianling 

TITLE=Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.961539

DOI=10.3389/fonc.2022.961539

ISSN=2234-943X

ABSTRACT=Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver gene and neoadjuvant targeted therapy is increasingly being investigated. Though neoadjuvant targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant targeted therapy to BRAF V600E mutation on NSCLC so far. Here, we report the first case of successful neoadjuvant targeted therapy with BRAF and MEK inhibitors followed by radical surgical excision with major pathologic response(MPR) in a patient with stage ⅢA  lung adenocarcinoma (LUAD) harboring BRAF V600E mutation. The case informs us that targeted therapy with BRAF and MEK inhibitors could be administrated as a neoadjuvant strategy for selected cases of NSCLC harboring BRAF V600E mutation.